- Phosphorex, a drug delivery-focused CDMO, has received a strategic investment from NOF CORPORATION.
- The investment will accelerate Phosphorex’s cGMP capabilities and strengthen its global position in nanoparticle-based drug delivery.
Phosphorex, a contract development and manufacturing organization (CDMO) specializing in drug delivery, announced today that NOF CORPORATION has completed a strategic investment in the company. This investment, backed by Ampersand Capital Partners, marks a crucial step in Phosphorex’s expansion efforts.
The partnership aims to accelerate the establishment of Phosphorex’s current good manufacturing practice (cGMP) capabilities, reinforcing the collaboration between the two companies. The addition of NOF CORPORATION as a shareholder highlights its confidence in Phosphorex’s innovative nanoparticle-based drug delivery solutions, which are poised for global impact.
“We are excited to welcome NOF CORPORATION as a minority shareholder,” stated Jarlath Keating, CEO of Phosphorex. “Their support and expertise will be invaluable as we continue our vision of enabling the development of novel therapeutics to improve the lives of patients. This partnership will help us advance our growth plans and enhance the value we provide to our clients and stakeholders.”
Yuji Yamamoto, General Manager of the Life Science division at NOF CORPORATION, also expressed optimism about the collaboration. “This investment is expected to bring numerous benefits to Phosphorex, including increased funding, additional strategic support, and other advantages. The collaboration with NOF CORPORATION will further enable Phosphorex’s mission to become the leading CDMO for nanoparticle-based drug delivery solutions and consolidate NOF’s position in the lipid nanoparticle (LNP)-based drug delivery market via its COATSOME® SS Series of proprietary ionizable lipids.”
Overview of outsourcing trends 
